NasdaqCM - Nasdaq Real Time Price USD
Outlook Therapeutics, Inc. (OTLK)
1.8250
-0.0750
(-3.95%)
As of 1:41:40 PM EDT. Market Open.
Insider Roster
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
| Individual or Entity | Most Recent Transaction | Date | Shares Owned as of Transaction Date |
|---|---|---|---|
| EVANSON JEFF Officer | Purchase | Mar 7, 2024 | 808,459 |
| HADDADIN YEZAN MUNTHER Director | Purchase | Mar 28, 2024 | 5,048 |
| KENYON LAWRENCE A. Chief Financial Officer | Purchase | Sep 26, 2024 | 5,946 |
| SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 27, 2025 | -- |
| SYNTONE VENTURES, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 15, 2024 | 1,705,440 |
Related Tickers
RIGL Rigel Pharmaceuticals, Inc.
22.18
+1.49%
KALV KalVista Pharmaceuticals, Inc.
14.69
-0.47%
NUVB Nuvation Bio Inc.
2.5700
+2.60%
UNCY Unicycive Therapeutics, Inc.
0.5735
-36.28%
VTGN Vistagen Therapeutics, Inc.
2.3850
+1.93%
GRCE Grace Therapeutics, Inc.
3.1100
-1.58%
NMRA Neumora Therapeutics, Inc.
1.0600
-2.74%
FBIO Fortress Biotech, Inc.
2.0700
-2.82%
APLT Applied Therapeutics, Inc.
0.3851
-2.50%
URGN UroGen Pharma Ltd.
7.00
-0.28%